12 Month Price Forecast For ILMN
Distance to ILMN Price Forecasts
ILMN Price Momentum
๐ค Considering Illumina (ILMN)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: February 15, 2025 4:19 PM UTC
ILMN Analyst Ratings & Price Targets
Based on our analysis of 34 Wall Street analysts, ILMN has a bullish consensus with a median price target of $144.10 (ranging from $100.00 to $247.00). The overall analyst rating is Buy (7.5/10). Currently trading at $100.24, the median forecast implies a 43.8% upside. This outlook is supported by 13 Buy, 10 Hold, and 2 Sell ratings.
The most optimistic forecast comes from Conor McNamara at RBC Capital, projecting a 146.4% upside. Conversely, the most conservative target is provided by Luke Sergott at Barclays, suggesting a 0.2% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ILMN Analyst Consensus
ILMN Price Target Range
Latest ILMN Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ILMN.
Date | Firm | Analyst | Rating | Change | Price Target |
---|---|---|---|---|---|
Feb 11, 2025 | Morgan Stanley | Tejas Savant | Equal-Weight | Maintains | $136.00 |
Feb 10, 2025 | Piper Sandler | David Westenberg | Overweight | Maintains | $190.00 |
Feb 10, 2025 | Barclays | Luke Sergott | Underweight | Downgrade | $100.00 |
Feb 7, 2025 | RBC Capital | Conor McNamara | Outperform | Maintains | $247.00 |
Feb 7, 2025 | Canaccord Genuity | Kyle Mikson | Hold | Maintains | $135.00 |
Feb 7, 2025 | Guggenheim | Subbu Nambi | Buy | Maintains | $150.00 |
Feb 3, 2025 | Barclays | Luke Sergott | Equal-Weight | Maintains | $130.00 |
Jan 13, 2025 | Morgan Stanley | Tejas Savant | Equal-Weight | Maintains | $150.00 |
Dec 11, 2024 | Citigroup | Patrick Donnelly | Neutral | Downgrade | $165.00 |
Nov 12, 2024 | Morgan Stanley | Tejas Savant | Equal-Weight | Reinstates | $156.00 |
Nov 12, 2024 | Stephens & Co. | Mason Carrico | Overweight | Maintains | $184.00 |
Nov 11, 2024 | Piper Sandler | David Westenberg | Overweight | Maintains | $185.00 |
Nov 6, 2024 | Baird | Catherine Ramsey | Neutral | Maintains | $139.00 |
Nov 5, 2024 | TD Cowen | Dan Brennan | Buy | Maintains | $177.00 |
Nov 5, 2024 | Citigroup | Patrick Donnelly | Buy | Maintains | $190.00 |
Nov 5, 2024 | JP Morgan | Julia Qin | Neutral | Maintains | $140.00 |
Nov 5, 2024 | Canaccord Genuity | Kyle Mikson | Hold | Maintains | $145.00 |
Nov 5, 2024 | UBS | John Sourbeer | Neutral | Maintains | $145.00 |
Nov 5, 2024 | Barclays | Luke Sergott | Equal-Weight | Maintains | $145.00 |
Nov 5, 2024 | RBC Capital | Conor McNamara | Outperform | Maintains | $254.00 |
Stocks Similar to Illumina Inc
The following stocks are similar to Illumina based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Illumina Inc (ILMN) Financial Data
Illumina Inc has a market capitalization of $16.12B with a P/E ratio of -13.0x. The company generates $4.37B in trailing twelve-month revenue with a -28.0% profit margin.
Revenue growth is -1.6% quarter-over-quarter, while maintaining an operating margin of -9.6% and return on equity of -30.1%.
Valuation Metrics
Growth & Margins
Financial Health
๐ฅ Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.

Illumina Inc (ILMN) Company Overview
About Illumina Inc
Provides genetic and genomic analysis solutions.
The company generates revenue through the sale of sequencing and array-based instruments, consumables, and services, targeting a diverse clientele including research centers, hospitals, and biotechnology firms. Its segments, Core Illumina and GRAIL, focus on various genomic solutions, including whole-genome sequencing and cancer detection tests.
Illumina's innovative products, such as the Galleri multi-cancer early detection test, position it at the forefront of genomic technology. With a strong market presence in the U.S., U.K., Singapore, and beyond, and ongoing development of cutting-edge solutions for cancer diagnosis, the company is well-positioned in the rapidly evolving biotech landscape.
Company Information
Sector
Healthcare
Industry
Diagnostics & Research
Employees
10,590
CEO
Mr. Jacob Thaysen Ph.D.
Country
United States
IPO Year
2000
Website
www.illumina.comIllumina Inc (ILMN) Latest News & Analysis
Zacks Style Scores can assist investors in selecting strong, market-beating stocks for their portfolios.
The Zacks Style Scores can guide investors in identifying high-potential stocks, enhancing portfolio performance and increasing the likelihood of achieving market-beating returns.
Zacks Style Scores provide a tool for investors to identify top-rated stocks aligned with their investment styles.
Zacks Style Scores provide a systematic approach to identify high-potential stocks, enhancing investment strategies and potentially improving returns.
Investors in Medical - Biomedical and Genetics stocks are evaluating Illumina (ILMN) and Alnylam Pharmaceuticals (ALNY) for potential value investment opportunities.
The comparison between Illumina and Alnylam highlights potential investment opportunities in the biomedical sector, influencing stock selection based on value and growth prospects.
Illumina shares dropped 15%, while competitors 10X Genomics and Pacific BioSciences fell 18% and 15%, respectively, reflecting a downturn in the gene-sequencing sector.
Illumina's 15% drop signals potential sector weakness, affecting rivals' valuations. This may prompt investors to reassess their positions in gene-sequencing stocks.
Why Illumina Stock Got Mashed on Monday
4 days agoIllumina (ILMN) shares fell nearly 6% on Monday due to a downgrade by an analyst, despite the S&P 500 rising 0.7%. This marks the second consecutive day of declines for the stock.
Illumina's stock decline amid a broader market rise signals potential investor concern over its fundamentals, impacting sentiment and future performance expectations.
Illumina's international revenue performance influences Wall Street analysts' forecasts, impacting future stock prospects and investor sentiment.
Illumina's international revenue impacts growth forecasts and market sentiment, influencing stock performance and investment strategies among analysts.
Frequently Asked Questions About ILMN Stock
What is Illumina Inc's (ILMN) stock forecast for 2025?
Based on our analysis of 34 Wall Street analysts, Illumina Inc (ILMN) has a median price target of $144.10. The highest price target is $247.00 and the lowest is $100.00.
Is ILMN stock a good investment in 2025?
According to current analyst ratings, ILMN has 13 Buy ratings, 10 Hold ratings, and 2 Sell ratings. The stock is currently trading at $100.24. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for ILMN stock?
Wall Street analysts predict ILMN stock could reach $144.10 in the next 12 months. This represents a 43.8% increase from the current price of $100.24. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Illumina Inc's business model?
The company generates revenue through the sale of sequencing and array-based instruments, consumables, and services, targeting a diverse clientele including research centers, hospitals, and biotechnology firms. Its segments, Core Illumina and GRAIL, focus on various genomic solutions, including whole-genome sequencing and cancer detection tests.
What is the highest forecasted price for ILMN Illumina Inc?
The highest price target for ILMN is $247.00 from Conor McNamara at RBC Capital, which represents a 146.4% increase from the current price of $100.24.
What is the lowest forecasted price for ILMN Illumina Inc?
The lowest price target for ILMN is $100.00 from Luke Sergott at Barclays, which represents a -0.2% decrease from the current price of $100.24.
What is the overall ILMN consensus from analysts for Illumina Inc?
The overall analyst consensus for ILMN is bullish. Out of 34 Wall Street analysts, 13 rate it as Buy, 10 as Hold, and 2 as Sell, with a median price target of $144.10.
How accurate are ILMN stock price projections?
Stock price projections, including those for Illumina Inc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.